Waystar Holding Corp. (WAY)
NEUTRALFundamental
60
Precio
$24.91
Capitalización Bursátil
$4.82B
Parte 1 · Cuánto vale la empresa
Resumen
Waystar Holding Corp. develops a cloud-based software solution for healthcare payments. Its platform offers financial clearance, patient financial care, claim and payer payment management, denials prevention and recovery, clinical integrity and revenue capture, and analytics and reporting solutions. It primarily serves healthcare industry. The company was founded in 2017 and is headquartered in Lehi, Utah.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance y Liquidez
Ingresos
$1.21B
Últimos 12 meses (hasta 30/6/2026)
Beneficio Neto
$135M
Últimos 12 meses (hasta 30/6/2026)
Flujo de Caja Libre
$283M
Patrimonio Neto Total
$3.88B
Pasivo Total
$1.91B
Ratio de Liquidez
1.85
Cobertura de Intereses
-
Deuda/EBITDA
3.80
Beneficio Por Acción
Ingresos y Beneficio Neto
Flujo de Caja Libre
Desglose de Ingresos
Estado histórico
Márgenes en el tiempo
La deuda en el tiempo
Cuánto pesa la deuda
Cuadro de crecimiento
Crecimiento — Ingresos
Estimación de Valor Justo
Valor Justo
$20.84
Precio Actual
$24.91
Margen de Seguridad
-19.5%
Rango de Valor Justo
$13.54 - $28.13
Métodos de Estimación
Métricas de Valoración
Ratio P/E
36.21
ROE
2.9%
Ratio P/B
1.22
P/FCF
19.74
Margen Bruto
-
ROIC
3.9%
Radar de Rentabilidad
Value Creation (Economic Moat)
ROIC
3.9%
WACC
8.4%
ROIC − WACC
-4.6 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Criterios de Análisis Fundamental
Superado (14)
- EPS shows upward trend
- P/FCF 19.74
- P/B Ratio 1.22
- Debt/Equity ratio
- Operating Margin 22.9%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- Analyst Consensus 93% Buy
- Earnings Surprise avg 2.5%
- Earnings Quality (OCF/NI) 2.17
- Net Margin Trend 11.2% vs 8.5%
Fallido (8)
- Price CAGR -17.46%
- ROIC 3.9%
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- ROE 3.6%
- Share Dilution 24.9%
- Piotroski F-Score 4/9
No disponible (5)
- Gross Margin NaN%
- Dividend Payout NaN%
- Interest Coverage
- Revenue Growth 5Y (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Señales mixtas: algunas áreas requieren atención
Calidad de los Beneficios
Alta calidad: beneficios respaldados por efectivo
Dilución de Acciones
Emitiendo nuevas acciones, diluyendo la participación
Gobernanza
Equipo Directivo
| Nombre | Cargo | Edad |
|---|---|---|
| Mr. Matthew J. Hawkins | CEO & Director | 53 |
| Mr. Steven M. Oreskovich CPA | Advisor | 53 |
| Mr. T. Craig Bridge | Chief Transformation Officer | 52 |
| Ms. Alpana Wegner C.P.A. | Chief Financial Officer | 52 |
| Mr. Edward Akira Parker | Head of Investor Relations | - |
| Mr. Mark Encinger | Vice President of Treasury & Compliance | - |
| Mr. Gregory R. Packer | Chief Legal Officer & Secretary | 45 |
| Kristin Lee | Vice President of Communications | - |
| Mr. Brendan O'Connor | Senior Vice President of Corporate Development & Strategy | - |
| Ms. Kim Wittman | Chief People Officer | 46 |
Riesgo de Auditoría
1
Riesgo del Consejo
6
Riesgo de Compensación
4
Riesgo de Derechos del Accionista
8
Parte 2 · El precio y el momento de entrar
Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.
Latest News
Recent headlines for WAY, sourced from Markets Gazette.
- 3/15/2026POSITIVEWaystar Stock Is Down 32% This Past Year, but One Fund Bought Up $11.5 Million Last Quarter
Despite a 32% stock decline over the past year, Waystar Holding Corp. has attracted significant investor interest, with one fund acquiring $11.5 million worth of shares in the last quarter. Waystar, a provider of cloud-based software for healthcare payment and revenue cycle management, appears to be viewed as undervalued by this particular investor. This substantial purchase, against a backdrop of recent poor stock performance, suggests a contrarian bet on the company's long-term prospects and its position within the healthcare technology sector.
via Markets Gazette